These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29467353)

  • 1. Can Tolvaptan Protect Renal Function in the Early Postoperative Period of Cardiac Surgery?　- Results of a Single-Center Randomized Controlled Study.
    Kishimoto Y; Nakamura Y; Harada S; Onohara T; Kishimoto S; Kurashiki T; Fujiwara Y; Nishimura M
    Circ J; 2018 Mar; 82(4):999-1007. PubMed ID: 29467353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of short-term administration of tolvaptan after open heart surgery.
    Matsuyama K; Koizumi N; Nishibe T; Iwasaki T; Iwahasi T; Toguchi K; Takahashi S; Iwahori A; Maruno K; Ogino H
    Int J Cardiol; 2016 Oct; 220():192-5. PubMed ID: 27379922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advent of New perioperative care for fluid management after cardiovascular surgery: A review of current evidence.
    Nishi H
    J Cardiol; 2020 Jun; 75(6):606-613. PubMed ID: 31980355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety Evaluation of Tolvaptan on Management of Fluid Balance after Cardiovascular Surgery Using Cardiopulmonary Bypass.
    Suehiro Y; Hosono M; Shibata T; Sasaki Y; Hirai H; Nakahira A; Kubota Y; Kaku D; Suehiro S
    Osaka City Med J; 2016 Dec; 62(2):111-119. PubMed ID: 30721586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolvaptan Reduces the Risk of Worsening Renal Function in Patients With Acute Decompensated Heart Failure and Preserved Left Ventricular Ejection Fraction　- Prospective Randomized Controlled Study.
    Tamaki S; Sato Y; Yamada T; Morita T; Furukawa Y; Iwasaki Y; Kawasaki M; Kikuchi A; Kondo T; Ozaki T; Seo M; Ikeda I; Fukuhara E; Abe M; Nakamura J; Fukunami M
    Circ J; 2017 Apr; 81(5):740-747. PubMed ID: 28202885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Tolvaptan on Fluid Management After Cardiovascular Surgery Using Cardiopulmonary Bypass.
    Ito H; Mizumoto T; Tempaku H; Fujinaga K; Sawada Y; Shimpo H
    J Cardiothorac Vasc Anesth; 2016 Dec; 30(6):1471-1478. PubMed ID: 27591907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tolvaptan in the early postoperative stage after heart valve surgery: results of the STAR (Study of Tolvaptan for fluid retention AfteR valve surgery) trial.
    Nishi H; Toda K; Miyagawa S; Yoshikawa Y; Fukushima S; Kawamura M; Yoshioka D; Saito T; Ueno T; Kuratani T; Sawa Y
    Surg Today; 2015 Dec; 45(12):1542-51. PubMed ID: 26411431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure.
    Kimura K; Momose T; Hasegawa T; Morita T; Misawa T; Motoki H; Izawa A; Ikeda U
    J Cardiol; 2016 May; 67(5):399-405. PubMed ID: 26692119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Tolvaptan Administration After Cardiac Surgery: A Meta-Analysis.
    Bellos I; Iliopoulos DC; Perrea DN
    J Cardiothorac Vasc Anesth; 2019 Aug; 33(8):2170-2179. PubMed ID: 30638918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peak Lag Between Plasma Vasopressin and Urine Aquaporin-2 Following Cardiac Surgery.
    Yokoyama S; Imamura T; Yamashita S; Doi T; Fukahara K; Yoshimura N; Kinugawa K
    Int Heart J; 2021 Sep; 62(5):1057-1061. PubMed ID: 34544990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction.
    Hanatani A; Shibata A; Kitada R; Iwata S; Matsumura Y; Doi A; Sugioka K; Takagi M; Yoshiyama M
    Heart Vessels; 2017 Mar; 32(3):287-294. PubMed ID: 27385022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of tolvaptan on renal excretion of electrolytes and urea nitrogen in patients undergoing coronary artery bypass surgery.
    Kato TS; Nakamura H; Murata M; Kuroda K; Suzuki H; Yokoyama Y; Shimada A; Matsushita S; Yamamoto T; Amano A
    BMC Cardiovasc Disord; 2016 Sep; 16(1):181. PubMed ID: 27624603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment　- Results From the K-STAR Study.
    Inomata T; Ikeda Y; Kida K; Shibagaki Y; Sato N; Kumagai Y; Shinagawa H; Ako J; Izumi T;
    Circ J; 2017 Dec; 82(1):159-167. PubMed ID: 28835586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First experience with Tolvaptan for the treatment of neonates and infants with capillary leak syndrome after cardiac surgery.
    Kerling A; Toka O; Rüffer A; Müller H; Habash S; Weiss C; Dittrich S; Moosmann J
    BMC Pediatr; 2019 Feb; 19(1):57. PubMed ID: 30755181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early introduction of tolvaptan after cardiac surgery: a renal sparing strategy in the light of the renal resistive index measured by ultrasound.
    Kato TS; Ono S; Kajimoto K; Kuwaki K; Yamamoto T; Amano A
    J Cardiothorac Surg; 2015 Nov; 10():143. PubMed ID: 26525900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tolvaptan add-on therapy in patients with acute heart failure: meta-analysis on randomised controlled trials.
    Ma G; Ma X; Wang G; Teng W; Hui X
    BMJ Open; 2019 May; 9(4):e025537. PubMed ID: 31048435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolvaptan can limit postoperative paroxysmal atrial fibrillation occurrence after open-heart surgery.
    Nakamura Y; Kishimoto Y; Harada S; Onohara T; Otsuki Y; Horie H; Nishimura M
    Surg Today; 2020 Aug; 50(8):841-848. PubMed ID: 31980932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolvaptan add-on therapy in patients with acute heart failure: A systematic review and meta-analysis.
    Luo X; Jin Q; Wu Y
    Pharmacol Res Perspect; 2020 Jun; 8(3):e00614. PubMed ID: 32500625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
    Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
    JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Impact of Tolvaptan on Intracellular and Extracellular Water in Chronic Kidney Disease Patients with Fluid Retention.
    Masuda T; Murakami T; Igarashi Y; Okabe K; Kobayashi T; Takeda SI; Saito T; Sekiguchi C; Miyazawa Y; Akimoto T; Saito O; Muto S; Nagata D
    Intern Med; 2016; 55(19):2759-2764. PubMed ID: 27725533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.